Guidance for the use of Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV acquisition in British Columbia

(Guidelines are for information purposes only, and do not imply BC-CfE endorsement or recommendations regarding provincial funding of PrEP in British Columbia)

Background

Pre-exposure prophylaxis (PrEP) refers to the use of daily oral antiretroviral therapy (ART) by HIV negative individuals to reduce the risk of acquiring HIV infection. In this context, PrEP refers to ongoing use of ART prior to (and after) potential exposure to HIV, which differs from standard post-exposure prophylaxis (PEP) where a short course of ART is used following high-risk exposure. Since 2010, four randomized controlled trials involving men who have sex with men (MSM), heterosexual HIV-serodiscordant couples, and people who inject drugs (PWID) have been published showing efficacy of tenofovir-based PrEP (alone or in combination with emtricitabine) as part of an HIV prevention package in individuals with high levels of adherence to medication [1, 2, 3, 4]. Tenofovir-emtricitabine (Truvada) was approved by the US Food and Drug Administration for use as PrEP on the basis of the results of the iPrEx trial [1] in July of 2012 [5]. The United States Centers for Disease Control and Prevention (US CDC) then published interim guidance for the use of PrEP for MSM, which has since been updated to include heterosexual HIV-serodiscordant couples and the PWID population [6, 7] following the results of The Partners PREP Trial, The TDF2 Trial, and the Bangkok Tenofovir Study [2-4]. In 2014, the US CDC released comprehensive clinical practice guidelines for the use of PrEP in the United States [8].

In 2012, the World Health Organization (WHO) released guidance on the use of PrEP for MSM, serodiscordant couples, and transgender females [9]. These guidelines were formulated by WHO in order to encourage demonstration projects aimed at better understanding the societal, cultural and individual factors that may influence the success or failure of PrEP as an HIV prevention tool.
Currently, no antiretroviral medications in Canada are licensed specifically for PrEP; however, physicians may choose to prescribe these medications for off-label use, and individuals who receive a prescription for PrEP may pay for it themselves, or in some instances may receive coverage through third-party (private) insurance plans. As such, the Therapeutic Guidelines Committee has been tasked to provide guidance for the use of tenofovir-emtricitabine in the context of PrEP. This information is provided to assist physicians in determining how to use and appropriately monitor patients who are receiving PrEP. It is important to note the development of this document does not imply any recommendations regarding funding of PrEP in British Columbia.

Guidance on the use of HIV Pre-Exposure Prophylaxis (PrEP)
(Adapted from references 6,7,8)

Before starting PrEP

- Confirm that patient is at ongoing, high risk for acquiring HIV infection.
  - For MSM, this will usually consist of having one or more of the following:
    - One or more HIV-positive sexual partner(s), particularly if the HIV positive partner is not receiving stable ART and/or does not have a consistently undetectable viral load\(^1\)
    - Recent (within 6 months) sexually transmitted infection (STI)
    - Multiple sex partners
    - History of inconsistent or no condom use for anal intercourse
    - Repeated courses of non-occupational post-exposure prophylaxis (nPEP)
  - For heterosexual men or women, this will usually consist of one or more of the following:
    - One or more HIV-positive sexual partner(s), particularly if the HIV

---

\(^1\) For individuals in a stable, monogamous relationship with an HIV positive individual, the use of effective antiretroviral therapy by the HIV positive individual as demonstrated by a sustained undetectable HIV viral load has been shown to significantly reduce the risk of HIV transmission by 96% [10]. The added value of PrEP in this setting has not been evaluated, but should be discussed.
positive partner is not receiving stable ART and/or does not have a consistently undetectable viral load\(^1, 2\)

- Having sexual partners who are MSM or use injection drugs

  o For people who use injection drugs, this will usually consist of:
    - Sharing injection equipment
    - Injecting once or more times per day in an unsafe setting (outside of safe injection sites)
    - Injecting cocaine or methamphetamine
    - Repeated courses of non-occupational post-exposure prophylaxis (nPEP)

- Confirm negative HIV antibody test immediately before starting PrEP medication, using a 4\(^{th}\) generation HIV Antibody/Antigen enzyme immunoassay (EIA).
  - If symptoms suggestive of acute HIV infection within the previous 6 weeks are present, and/or history of high-risk unprotected sex in the previous month, a pooled nucleic acid amplification test (NAAT) for HIV RNA is recommended. This test can be arranged by contacting a virologist at the BC Centre for Disease Control (BCCDC) (604-707-5600). Defer PrEP initiation until acute HIV infection is ruled out.

- For heterosexual women, determine if there are immediate plans to become pregnant, or if the woman is currently pregnant or breastfeeding, as this may alter the risk/benefit ratio for PrEP\(^2\).

- Confirm adequate renal function: calculated creatinine clearance or estimated glomerular filtration rate (eGFR) \(\geq 60\) mL per minute, and absence of proteinuria on urinalysis and/or quantitative test (urine albumin to creatinine ratio [UACR]).

---

\(^2\) For HIV serodiscordant couples planning to become pregnant, pre-assessment counselling regarding the use of PrEP should include information on maximal risk reduction, alternate options for conception and ensuring that timing of intercourse is planned around most fertile period of the menstrual cycle. Clinicians should contact a qualified specialist or The Oak Tree Clinic at BC Women’s Hospital (604-875-2212; 1-888-711-3030) for more detailed information.
• Screen for hepatitis B and C virus (see Table 2) and vaccinate against hepatitis B if non-immune. If hepatitis B infection is diagnosed, refer for expert opinion regarding need for hepatitis B treatment.

• Screen and treat for other sexually transmitted infections (STIs: gonorrhea, chlamydia, syphilis).

• Review current medications for drug interactions and overlapping toxicities with tenofovir (TDF)/emtricitabine (FTC). Since TDF and FTC are primarily renally eliminated, there is a potential for drug interaction and increased nephrotoxicity with other agents that can affect renal function or compete for active tubular secretion, e.g. acyclovir, valacyclovir, cidofovir, ganciclovir, valganciclovir, aminoglycosides, non-steroidal anti-inflammatory drugs (NSAIDS) [11].

• As TDF has been associated with decreases in bone mineral density in both HIV treatment and PrEP settings [12-14], it should be used with caution in persons with a history of fragility fractures or significant risk factors for osteoporosis.

• Counsel with regard to adherence, risk reduction, and need to seek immediate attention for management if symptoms of acute HIV develop.

Prescribing PrEP medication

• Prescribe 1 tablet of Truvada (tenofovir disoproxil fumarate (TDF) 300 mg with emtricitabine (FTC) 200 mg) to be taken once per day. As there are currently no data available regarding the efficacy of intermittent or event-driven PrEP, it is recommended that TDF/FTC should be prescribed and taken on a regular daily basis.

• Prescribe a 30-day supply initially, then reassess for adherence and tolerability. Prescriptions should be renewed only after repeat HIV testing confirms that the patient remains HIV-negative and eligibility criteria persist. Repeat prescriptions should be provided and reassessment performed at intervals not longer than 90
days.

- For women, ensure that pregnancy test is negative or, if pregnant, that the patient has been informed about the potential risks and benefits of PrEP during pregnancy.

- Provide additional HIV risk-reduction and PrEP medication-adherence counseling and condoms.
  - Adherence counselling should emphasize that efficacy of PrEP was greatly reduced amongst individuals who did not take the medication as prescribed, i.e. one pill once-a-day.
  - The time from initiation of daily oral doses of TDF/FTC to maximal protection against HIV infection is unknown. However, pharmacokinetic data from HIV-infected individuals suggest that steady-state level in the rectal mucosa is reached after 7 days and in the cervico-vaginal mucosa after 20 days of initiating therapy [15, 16].

**Follow-up while PrEP is being prescribed**

- **After first month, then at least every 3 months thereafter:**
  - Monitor HIV antibody status using the 4th generation HIV Antibody/Antigen EIA and document negative status.
  - Assess for symptoms of acute HIV since last visit. If symptoms present, perform a pooled HIV RNA NAAT and consult with an expert physician regarding ongoing TDF/FTC use while awaiting test results.
  - Check serum creatinine and urinalysis and/or UACR. If there are signs of new persistent or worsening renal dysfunction, additional work up and consultation with a nephrologist are recommended.
At each follow-up visit for women, conduct a pregnancy test and document results; if pregnant, discuss continued use of PrEP with patient and prenatal care provider.

- Evaluate and support PrEP medication adherence at each follow-up visit, more often if inconsistent adherence is identified.
- Assess risk behaviours and provide risk-reduction counselling and condoms.

**At least every 6 months:**
- Test for STIs and hepatitis C even if asymptomatic, and treat as needed.

**Stopping PrEP**

- Order HIV antibody tests as above to document current HIV status.
- If HIV positive, order and document results of HIV resistance testing, and establish linkage to HIV care.
- If HIV negative, establish linkage to risk reduction support services as indicated.
- If patient is being treated for active hepatitis B, ensure appropriate specialist referral prior to stopping PrEP. If patient was receiving treatment for active hepatitis B prior to PrEP, these medications will need to be re-initiated for hepatitis B management following withdrawal of TDF/FTC.
- If pregnant, inform prenatal care provider of TDF/FTC use in early pregnancy and coordinate care to maintain HIV prevention during pregnancy and breastfeeding. Perform HIV testing in each trimester and prior to delivery to ensure seroconversion during pregnancy has not occurred.
(Guidelines are for information purposes only, and do not imply BC-CfE endorsement or recommendations regarding provincial funding of PrEP in British Columbia)

**Table 1: SUMMARY OF GUIDANCE FOR PREP USE IN BRITISH COLUMBIA** (Adapted from Reference 8)

<table>
<thead>
<tr>
<th></th>
<th>Men who have sex with men</th>
<th>Heterosexual men and women</th>
<th>People who use injection drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Detecting substantial risk of acquiring HIV infection</strong></td>
<td>HIV-positive sexual partner¹</td>
<td>HIV-positive sexual partner¹</td>
<td>HIV-positive injecting partner¹</td>
</tr>
<tr>
<td></td>
<td>Recent STI</td>
<td>Recent STI</td>
<td>Sharing injection equipment</td>
</tr>
<tr>
<td></td>
<td>Multiple sex partners</td>
<td>Multiple sex partners</td>
<td></td>
</tr>
<tr>
<td></td>
<td>History of inconsistent or no condom use</td>
<td>History of inconsistent or no condom use</td>
<td></td>
</tr>
<tr>
<td><strong>Clinically eligible</strong></td>
<td>Documented negative HIV test result before prescribing PrEP</td>
<td>Documented negative HIV test result before prescribing PrEP</td>
<td>Documented negative HIV test result before prescribing PrEP</td>
</tr>
<tr>
<td></td>
<td>No signs/symptoms of acute HIV infection</td>
<td>No signs/symptoms of acute HIV infection</td>
<td>No signs/symptoms of acute HIV infection</td>
</tr>
<tr>
<td></td>
<td>Normal renal function; no contraindicated medications</td>
<td>Normal renal function; no contraindicated medications</td>
<td>Normal renal function; no contraindicated medications</td>
</tr>
<tr>
<td></td>
<td>Documented hepatitis B virus infection status and vaccination status</td>
<td>Documented hepatitis B virus infection status and vaccination status</td>
<td>Documented hepatitis B virus infection status and vaccination status</td>
</tr>
<tr>
<td><strong>Prescription</strong></td>
<td>Daily, continuing, oral doses of tenofovir/emtricitabine (Truvada); 30-day supply initially, then ≤90-day supply on a continuing basis if adherence, tolerability, and eligibility confirmed</td>
<td>Daily, continuing, oral doses of tenofovir/emtricitabine (Truvada); 30-day supply initially, then ≤90-day supply on a continuing basis if adherence, tolerability, and eligibility confirmed</td>
<td>Daily, continuing, oral doses of tenofovir/emtricitabine (Truvada); 30-day supply initially, then ≤90-day supply on a continuing basis if adherence, tolerability, and eligibility confirmed</td>
</tr>
<tr>
<td><strong>Other services</strong></td>
<td>Follow-up visits after 1 month and at least every 3 months thereafter, to provide the following: HIV test, assess renal function, medication adherence counselling, behavioural risk reduction support, side effect assessment, STI symptom assessment</td>
<td>Follow-up visits after 1 month and at least every 3 months thereafter, to provide the following: HIV test, assess renal function, medication adherence counselling, behavioural risk reduction support, side effect assessment, STI symptom assessment</td>
<td>Follow-up visits after 1 month and at least every 3 months thereafter, to provide the following: HIV test, assess renal function, medication adherence counselling, behavioural risk reduction support, side effect assessment, STI symptom assessment</td>
</tr>
<tr>
<td></td>
<td>Every 6 months, test for STIs</td>
<td>Every 6 months, test for STIs</td>
<td>Every 6 months, test for STIs</td>
</tr>
<tr>
<td></td>
<td>Do oral/rectal STI testing</td>
<td>Do oral/rectal STI testing</td>
<td>Do oral/rectal STI testing</td>
</tr>
<tr>
<td></td>
<td>Assess pregnancy intent</td>
<td>Assess pregnancy intent</td>
<td>Assess pregnancy intent</td>
</tr>
<tr>
<td></td>
<td>Pregnancy test every 3 months</td>
<td>Pregnancy test every 3 months</td>
<td>Pregnancy test every 3 months</td>
</tr>
<tr>
<td></td>
<td>Access to clean needles/syringes and drug treatment services</td>
<td>Access to clean needles/syringes and drug treatment services</td>
<td>Access to clean needles/syringes and drug treatment services</td>
</tr>
</tbody>
</table>

¹ For individuals in a stable, monogamous relationship with an HIV positive individual, the use of effective antiretroviral therapy by the HIV positive individual as demonstrated by a sustained undetectable HIV viral load has been shown to significantly reduce the risk of HIV transmission by 96% [10]. The added value of PrEP in this setting has not been evaluated.
Table 2: Summary of testing recommendations during PreP

<table>
<thead>
<tr>
<th>Assay Type</th>
<th>Baseline</th>
<th>After first month then Q3 months</th>
<th>Q 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Serology (4th Generation Antibody/Antigen Assay)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>HIV RNA Pooled NAAT Test - for those with symptoms of acute HIV</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Screen (Hepatitis B Surface Antigen, surface antibody, core antibody)*</td>
<td>X*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis C Screen (Hepatitis C Antibody)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Gonorrhea screen^ (urine GC NAT test, throat and rectal swabs for GC depending on type of sexual activity reported)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Chlamydia Screen ^ (Chlamydia urine NAT test)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Syphilis Screen^ (T. pallidum EIA)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Creatinine and urinalysis</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

* Hepatitis B Vaccine should be initiated in unvaccinated individuals. ^ Individuals diagnosed with concurrent STI should be offered standard therapy following Provincial Guidelines.
References


